Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Read
Regeneron (REGN) Tops Q2 Earnings And Revenue Estimates
Article By:
Zacks Investment Research
Wednesday, August 5, 2020 10:09 AM EDT
Regeneron came out with quarterly earnings of $7.16 per share.
In this article: REGN
REGN Flat Despite Covid-19 Antibody Drug Update
Article By:
Schaeffers Research
Tuesday, August 4, 2020 11:00 AM EDT
The equity is up over 115% year-over-year.
In this article: REGN
Quick Reminder: Insider Trading Does Not Maximize Shareholder Value
Article By:
Dean Baker
Sunday, July 26, 2020 7:39 PM EDT
Insider trading effectively means top executives are stealing from the companies they run. Excitement over potential covid vaccines may be causing irregularities at at least 9 biopharmas, according to the NYT.
Allakos Drops After Regeneron Eosinophilic Esophagitis Study Hits Endpoints
Article By:
The Fly
Tuesday, May 26, 2020 12:17 PM EDT
Shares of Allakos are lower after Regeneron Pharmaceuticals announced yesterday that Part A of a Phase 3 trial evaluating Dupixent in patients 12 years and older with eosinophilic esophagitis met both of its co-primary endpoints.
Regeneron Pharmaceuticals’ Dupixent Has Multi-Billion-Dollar Potential: Polen Capital
Note it has only been approved in Japan. And only for those whom existing treatments are ineffective. So that's a MUCH smaller market. How small I don't know. But not enough to make me bite. $REGN